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Metabolically healthy obesity (MHO) and metabolically healthy overweight (MH-OW) have been suggested to be
important and emerging phenotypes with an increased risk of cardiovascular disease (CVD). However, whether MHO and
MH-OW are associated with all-cause mortality remains inconsistent.
The association of MHO and MH-OW and all-cause mortality was determined in a Chinese community-based prospective
cohort study (the Kailuan study), including 93,272 adults at baseline. Data were analyzed from 2006 to 2017. Participants
were categorized into 6 mutually exclusive groups, according to BMI and metabolic syndrome (MetS) status. The primary
outcome was all-cause death, and accidental deaths were excluded.
During a median follow-up of 11.04 years (interquartile range, 10.74–11.22 years), 8977 deaths occurred. Compared with
healthy participants with normal BMI (MH-NW), MH-OW participants had the lowest risk of all-cause mortality
(multivariate-adjusted HR [aHR], 0.926; 95% CI, 0.861–0.997), whereas there was no increased or decreased risk for
MHO (aHR, 1.009; 95% CI, 0.886–1.148). Stratified analyses and sensitivity analyses further validated that there was a
nonsignificant association between MHO and all-cause mortality.
Overweight and obesity do not predict increased risk of all-cause mortality in metabolic healthy Chinese individuals.
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Introduction
Overweight and obesity have become serious public health issue in both developed and developing coun-
tries (1, 2). Studies have shown that overweight and obesity are independent risk factors for cardiovascular 
diseases, including coronary disease, myocardial infarction, ischemic heart disease, and malignant tumors 
(3–9). Two systematic reviews and meta-analyses, including at least 230 prospective studies, showed that 
overweight and obesity were associated with increased risk of  all-cause mortality (10, 11); these findings 
were consistent with a study of  1.46 million White adults (12). Moreover, linear Mendelian randomiza-
tion analyses have indicated that an increase of  1 unit in genetically predicted BMI gave rise to a 5%–9% 
increased mortality risk in overweight and obese participants (13). However, a recent 22-year cohort study 
found that being overweight had no effect on all-cause mortality; in particular, it was protective effect 
in men or people aged 30–39 years (14). A large population-based cohort study found that BMI had a 
J-shaped association with all-cause mortality, and the lowest risk occurred in the range 21–25 kg/m2 (15). A 
meta-analysis, including 20 prospective cohort studies, indicated that overweight and obesity were inversely 
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associated with all-cause mortality with acute myocardial infarction history (16). Several large population 
meta-analyses findings, including at least 50 prospective studies, also produced the same results (17, 18). 
Therefore, the “obesity paradox” has been commonly identified in observational studies.
There is heterogeneity among overweight or obese individuals. Some have worse metabolic profiles and 
increased health risks; others have healthier metabolic profiles and decreased health risks. Combined BMI 
and metabolic profiles in individuals have been categorized into 6 groups: metabolically healthy normal 
weight (MH-NW), metabolically healthy overweight (MH-OW), metabolically healthy obesity (MHO), 
metabolically unhealthy normal weight (MUH-NW), metabolically unhealthy overweight (MUH-OW), 
and metabolically unhealthy obesity (MUO) (19–22). Thus, all obesity statuses are not equal.
In a previous study, we found that obesity was associated with myocardial infarction in a Chinese 
population, regardless of  whether measurable metabolic abnormalities were present (21). This finding 
was consistent with those in several reports that aimed to identify a healthy obesity phenotype related to 
cardiovascular diseases (23–25). The studies about association of  MH-OW or MHO phenotype with all-
cause mortality risk were reported, but the results were inconsistent (26–28). Several studies have shown 
that MH-OW and MHO were not significantly associated with an increased risk of  all-cause mortality 
(MH-NW as the control) (27, 29, 30). In contrast, another study demonstrated that MHO and MH-OW 
were not benign conditions (28). Moreover, the association of  MHO or MH-OW with all-cause mortali-
ty has not been investigated in a Chinese population. In this study, we aimed to explore the association 
between MHO or MH-OW and all-cause mortality in the Kailuan study, a longitudinal study with 101,510 
participants and more than 10 years of  follow-up.
Results
Participants with missing data (n = 6539) or BMIs of  less than 18.5 kg/m2 (n = 1699) were excluded. Some 
individuals met more than 1 exclusion criterion. A total of  93,272 eligible participants were finally included 
in the analyses (Figure 1).
Among the 93,272 eligible participants, 80,569 (86.38%) were metabolically healthy. MH-OW and 
MHO statuses represented 36.17% (n = 33,736) and 14.22% (n = 13,266) of  the total samples, respectively. 
The demographic and biochemical characteristics of  the participants are presented in Table 1. Compared 
with MH-NW individuals, MH-OW and MHO individuals had a history of  disease and a higher propor-
tion of  older individuals, men, and drinkers. The levels of  HDL cholesterol (HDL-C) and education in the 
MH-OW and MHO groups were significantly lower than those in the MH-NW groups. In addition, higher 
blood pressure, triglyceride (TG), waist circumference (WC), LDL, and salt intake levels were also found 
in the MH-OW and MHO groups (Table 1). In addition, MH-OW and MHO individuals had a higher 
proportion of  abnormal measures in other indices of  disease, including LDL cholesterol (LDL-C), fasting 
blood glucose (FBG), TG, and HDL-C, compared with those in MH-NW individuals (P < 0.001) (Table 1).
After a median follow-up period of  11.04 years (interquartile range, 10.74–11.22 years), 8977 deaths 
occurred. The incidences of  all-cause death per 1000 person-years were 9.84 in the MH-NW group, 9.31 in 
the MH-OW group, 9.94 in the MHO group, 13.95 in the MUH-NW group, 11.59 in the MUH-OW group, 
and 11.65 in the MUO group. As shown in Figure 2, all-cause mortality was highest in the MUH-NW 
group and the lowest in the MH-OW group. In the crude Cox model, compared with participants in the 
MH-NW group, participants were at a 5.5% lower risk (HR, 0.945; 95% CI, 0.899–0.993) in the MH-OW 
group, at no risk (HR, 1.009; 95% CI, 0.945–1.076) in the MHO group, at a 42.7% higher risk (HR, 1.427; 
95% CI, 1.269–1.605) in the MUH-NW group, at a 17.8% higher risk (HR, 1.178; 95% CI, 1.084–1.281) in 
the MUH-OW group, and at a 18.5% higher risk (HR, 1.185; 95% CI, 1.078–1.302) in the MUO group for 
all-cause mortality (Figure 3). After adjustment for sex, age, WC, history of  disease, socioeconomic status, 
lifestyle factors, and dyslipidemia, the HRs for all-cause mortality were 0.926 (95% CI, 0.861–0.997) in 
the MH-OW group, 1.009 (95% CI, 0.886–1.148) in the MHO group, 1.311 (95% CI, 1.162–1.479) in the 
MUH-NW group, 1.135 (95% CI, 1.023–1.260) in the MUH-OW group, and 1.252 (95% CI, 1.075–1.458) 
in the MUO group, compared with the MH-NW group (Figure 3).
In the sensitivity analyses, we first carried out the main analysis among participants with no smoking 
habit at baseline, and similar results were obtained (Figure 4). The adjusted HRs were 0.895 (95% CI, 
0.819–0.978) in the MH-OW group, 0.969 (95% CI, 0.828–1.133) in the MHO group, and 1.310 (95% CI, 
1.136–1.510) in the MUH-NW, compared with the MH-NW group (Figure 4A). The sensitivity analyses 
also showed similar results after the exclusion of  participants who died during the first 2 years of  follow-up 
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(Figure 4B). Furthermore, we redefined obesity and metabolic syndrome (MetS) and obtained similar 
results. Compared with MH-NO individuals, MHO individuals had no significantly increased risk of  all-
cause mortality (HR, 0.921, 95% CI, 0.742–1.144), whereas MU-NO and MUO individuals had a signifi-
cantly increased risk of  all-cause mortality (MU-NO, HR, 1.207, 95% CI 1.128–1.291; MUO, HR, 1.393, 
95% CI 1.146–1.692, respectively) after controlling for all confounding factors (Figure 4C). In addition, the 
results showed that, for participants aged 50–85 years, adjusted HRs were 0.937 (95% CI, 0.866–1.014) in 
the MH-OW group, 0.993 (95% CI, 0.863–1.142) in the MHO group, and 1.257 (95% CI, 1.105–1.430) in 
the MUH-NW, compared with the MH-NW group (Figure 4D).
In the stratified analyses, compared with that in the MH-NW group, MH-OW was associated with 
significantly decreased risk of  all-cause mortality in women (HR, 0.732, 95% CI, 0.544–0.986), but 
there was no increased or decreased risk in men (HR, 0.938, 95% CI, 0.869–1.012). The association 
was significant in participants with a baseline age <65 years (HR, 0.895, 95% CI, 0.807–0.993) but not 
in those with baseline age ≥65 years (HR, 0.951, 95% CI, 0.857–1.055) (Table 2). Similarly, MHO was 
not significantly associated with an increased risk of  mortality in each stratum, and MUH remained 
the highest-risk phenotype for all-cause mortality. There were significant interactions of  age (<65 years 
old, ≥65 years old) and sex in relationship BMI-MetS phenotypes with all-cause mortality (P interac-
tion < 0.01 for both), but no interactions were found for smoking status, drinking status, or physical 
activity (P interaction > 0.05 for all) (Table 2).
Discussion
In a prospective cohort study with a median follow-up of  11 years, we found that MH-OW participants had 
the lowest risk of  all-cause mortality (HR, 0.926, 95% CI, 0.861–0.997) and participants MHO participants 
did not have an increased risk of  all-cause mortality (HR, 1.009, 95% CI, 0.886–1.148), while MUH-NW 
participants had the highest risk of  all-cause mortality (HR, 1.311, 95% CI, 1.162–1.479) compared with 
the MH-NW participants, after adjusting for sex, age, WC, history of  disease, socioeconomic status, life-
style factors, and dyslipidemia. The sensitivity and stratification analyses further validated these findings. 
To our knowledge this is the first large population study to demonstrate that overweight and obesity do not 
predict an increased risk of  all-cause mortality in a metabolically healthy Chinese population.
Figure 1. The flow diagram of study participants. 
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Table 1. Baseline characteristics of participants according to BMI-MetS phenotypes
Characteristic MH-NW 
(n = 33567)
MH-OW 
(n =33736)
MHO 
(n = 13266)
MUH-NW 
(n = 2289)
MUH-OW 
(n = 5975)
MUO 
(n = 4439)
PA PB
Age, yr, median (IQR) 50.77 (16.16) 51.63 (14.77) 51.22 (16.00) 54.77 (13.99) 54.21 (12.08) 53.56 (12.22)  <0.001 0.007
Men, no. (%) 26153 (77.91) 29368 (87.05) 11770 (88.72) 1196 (52.25) 3488 (58.38) 2580 (58.12)  <0.001  <0.001
BMI, kg/m2, median (IQR) 22.10 (2.26) 25.73 (1.91) 29.41 (2.28) 22.79 (1.73) 26.08 (1.94) 29.97 (2.68)  <0.001  <0.001
WC, cm, median (IQR) 80 (10) 88 (9) 96 (11) 84 (9) 89 (9) 97 (11)  <0.001  <0.001
LDL-C, mmol/L, median (IQR) 2.27 (1.01) 2.40 (0.95) 2.40 (0.97) 2.30 (1.04) 2.40 (1.10) 2.43 (1.08)  <0.001  <0.001
FBG, mmol/L, median (IQR) 4.99 (0.87) 5.10 (0.89) 5.10 (0.88) 6.01 (1.51) 6.10 (1.63) 6.11 (1.65)  <0.001  <0.001
TG, mmol/L, median (IQR) 1.02 (0.66) 1.27 (0.84) 1.45 (1.04) 2.20 (1.48) 2.31 (1.50) 2.37 (1.53)  <0.001  <0.001
HDL-C, mmol/L, median (IQR) 1.56 (0.49) 1.49 (0.45) 1.45 (1.04) 1.49 (0.59) 1.48 (0.52) 1.44 (0.51)  <0.001  <0.001
LDL-C, no. (%)C
≤2.03 mmol/L 12685 (37.81) 10316 (30.61) 3928 (29.64) 833 (36.50) 1876 (31.57) 1320 (29.90)
 <0.001  <0.0012.03–2.66 mmol/L 10979 (32.73) 11795 (35.00) 4545 (34.30) 710 (31.11) 1820 (30.62) 1394 (31.58)
>2.66 mmol/L 9885 (29.46) 11589 (34.39) 4778 (36.06) 739 (32.38) 2247 (37.81) 1700 (38.51)
FBG, no. (%)C
≤4.83 mmol/L 13846 (41.25) 11757 (34.85) 4364 (32.90) 291 (12.71) 593 (9.92) 424 (9.55)
 <0.001  <0.0014.83–5.49 mmol/L 11956 (35.62) 12545 (37.19) 4984 (37.57) 231 (10.09) 572 (9.57) .66)
>5.49 mmol/L 7765 (23.13) 9434 (27.96) 3918 (29.53) 1767 (77.20) 4810 (80.50) 3586 (80.78)
TG, no. (%) c
≤1.02 mmol/L 16858 (50.22) 10533 (31.22) 2825 (21.30) 185 (8.08) 298 (4.99) 169 (3.81)
 <0.001  <0.0011.02–1.65 mmol/L 11351 (33.82) 13409 (39.75) 5304 (39.98) 223 (9.74) 519 (8.69) 418 (9.42)
>1.65 mmol/L 5358 (15.96) 9794 (29.03) 5137 (38.72) 1881 (82.18) 5158 (86.33) 3852 (86.78)
HDL-C, no. (%) c
≤1.35 mmol/L 9399 (28.00) 11416 (33.84) 5083 (38.32) 853 (37.27) 2232 (37.36) 1812 (40.82)
 <0.001  <0.0011.35–1.66 mmol/L 11169 (33.27) 11848 (35.12) 4560 (34.37) 615 (26.87) 1831 (30.64) 1322 (29.78)
>1.66 mmol/L 12999 (38.73) 10472 (31.04) 3623 (27.31) 821 (35.87) 1912 (32.00) 1305 (29.40)
SBP, mmHg, median (IQR) 120 (25) 129.30 (21.40) 130.70 (30) 140 (20) 140 (26) 142 (29.30)  <0.001  <0.001
DBP, mmHg, median (IQR) 80 (14.30) 80.70 (10.70) 85 (15) 88 (11.30) 90 (16.70) 90 (18.70)  <0.001  <0.001
Current smoking, no. (%) 12076 (35.98) 12316 (36.51) 4690 (35.35) 543 (23.72) 1546 (25.87) 1099 (24.76) 0.152 0.206
Current drinking, no. (%) 12627 (37.62) 13483 (39.97) 5237 (39.48) 595 (25.99) 1712 (28.65) 1248 (28.11)  <0.001  <0.001
University or college or above, 
no. (%)
2731 (8.14) 2194 (6.50) 878 (6.62) 87 (3.80) 259 (4.33) 200 (4.51)  <0.001  <0.001
Family per-member income 
≥800Yuan/mo., no. (%)
4747 (14.14) 4858 (14.40) 1936 (14.59) 305 (13.32) 920 (15.40) 658 (14.82) 0.338 0.208
Physical activity, ≥3times /
week, no. (%)
5064 (15.09) 5257 (15.58) 2058 (15.51) 415 (18.13) 1093 (18.29) 812 (18.29) 0.074 0.246
Salt intake >12 g/d, no. (%) 3302 (9.84) 3768 (11.18) 1674 (12.63) 187 (8.18) 639 (10.71) 569 (12.84)  <0.001  <0.001
History of hypertension, no. (%) 2306 (6.87) 4122 (12.22) 2336 (17.61) 495 (21.63) 1702 (28.49) 1577 (35.53)  <0.001  <0.001
History of diabetes, no. (%) 545 (1.62) 800 (2.37) 307 (2.31) 274 (11.97) 703 (11.77) 506 (11.40)  <0.001  <0.001
History of hyperlipidemia, 
no. (%)
1060 (3.16) 1959 (5.81) 1143 (8.62) 263 (11.49) 865 (14.48) 769 (17.32)  <0.001  <0.001
History of myocardial 
infarction, no. (%)
278 (0.83) 465 (1.38) 230 (1.73) 44 (1.92) 124 (2.08) 108 (2.43)  <0.001  <0.001
History of stroke, no. (%) 679 (2.03) 886 (2.63) 383 (2.89) 76 (3.32) 224 (3.75) 191 (4.30) <0.001  <0.001
Data represent median (interquartile range [IQR] 25%–75%) or number and percentage. MH-NW, metabolically healthy normal weight; MUH-NW, metabolically 
unhealthy normal weight; MH-OW, metabolically healthy overweight; MUH-OW, metabolically unhealthy overweight; MHO, metabolically healthy obesity; 
MUO, metabolically healthy obesity; WC, waist circumference; FBG, fasting blood glucose; TG, triglycerides; TC, total cholesterol; HDL-C, HDL cholesterol; LDL-
C, LDL cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure. AP values between metabolically healthy normal weight and 
metabolically healthy overweight groups. BP values between metabolically healthy normal weight and metabolically healthy obese groups. CData were grouped by 
tertiles.
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The association between MHO and all-cause mortality has been widely investigated, but the findings 
remain inconsistent. A systemic review and meta-analysis, including 11 prospective studies from Europe, North 
America, and Asia (published from 1950 to June 5, 2013), indicated that MHO was not significantly associat-
ed with all-cause mortality and/or cardiovascular events (relative risk [RR]: 1.07, 95% CI, 0.92–1.25) but was 
significantly associated when only studies with at least 10 years of follow-up were included (RR, 1.24, 95% CI, 
1.02–1.55) (31). Another systematic review and meta-analysis (published up until September 30, 2015) demon-
strated that MHO was not associated with increased all-cause mortality risk (HR, 1.07; 95% CI, 0.92–1.25) (19). 
Recently, most studies have not favored the association between the MHO phenotype and an increased risk of  
all-cause mortality. A cohort study (54,089 participants, 12.8 years of follow-up) combining 5 cohort studies 
(Aerobics Center Longitudinal Study [ACLS], Coronary Artery Risk Development in Young Adults [CAR-
DIA], Multi-Ethnic Study of Atherosclerosis [MESA], National Health and Nutrition Examination Survey 
[NHANES III], and National Health and Nutrition Examination Survey Continuous [NHANES Continuous]) 
showed that obesity without other metabolic risk factors was not associated with an increased risk of all-cause 
mortality compared with lean healthy individuals (HR, 1.10, 95% CI 0.8–1.6) (32). The English Longitudinal 
Study of Ageing (5427 participants, 8 years of follow-up) also indicated that there was no significant association 
between MHO and all-cause mortality (HR, 1.14, 95% CI 0.83–1.52) (33). Another cohort study carried out in 
the United Kingdom (22,203 participants, follow-up 7 years) also revealed that the MHO phenotype (HR, 0.91; 
95% CI, 0.64–1.29) did not increase all-cause mortality risk compared with metabolically healthy individuals 
without obesity (27). A prospective cohort study in Finland (2185 men, 26 years of follow-up) demonstrated that 
MH-OW/obese men were not at increased risk of sudden cardiac death (HR, 0.95; 95% CI, 0.40–2.24) com-
pared with the MH-NW group (34). Consistent with these recent studies, the present study (93,272 participants, 
11 years of follow-up) verified no significant association between MHO and all-cause mortality in a Chinese 
population, suggesting that baseline obesity without MetS does not have adverse effects to all-cause mortality.
Contrary to the approximately well-defined association between MHO and all-cause mortality, the asso-
ciation between MH-OW and all-cause mortality is more complex. Previously described systemic review and 
meta-analysis has indicated that MH-OW was not significantly associated with all-cause mortality and/or 
cardiovascular events, in all studies (RR, 1.10, 95% CI, 0.90–1.24) or only in studies with at least 10 years of  
follow-up (RR, 1.21, 95% CI, 0.91–1.61) (31). Additionally, the cohort study (54,089 participants, 12.8 years 
of  follow-up) combining 5 cohort studies (ACLS, CARDIA, MESA, NHANES, and NHANES Continuous) 
showed that overweight without other metabolic risk factors was not associated with an increased risk of  
all-cause mortality compared with lean healthy individuals (HR, 0.95, 95% CI 0.7–1.2) (32). Most studies of  
Figure 2. The cumulative incidence of death according to the BMI-MetS phenotypes. MetS, metabolic syndrome; 
MH-NW, metabolically healthy normal weight; MUH-NW, metabolically unhealthy normal weight; MH-OW, metabol-
ically healthy overweight; MUH-OW, metabolically unhealthy overweight; MHO, metabolically healthy obesity; MUO, 
metabolically healthy obesity.
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the association between MH-OW and all-cause mortality demonstrated a negative relationship. The Reasons 
for Geographic and Racial Dereferences in Stroke (REGARDS) cohort study (22,514 participants, 6.5 years 
of  follow-up) demonstrated that the MH-OW phenotype (HR, 0.79; 95% CI, 0.63–0.98) was associated with 
a decreased risk of  cancer mortality (35). In contrast to these studies, we demonstrated that the MH-OW 
phenotype was associated with a decreased risk of  all-cause mortality (HR, 0.926; 95% CI, 0.861–0.997), 
suggesting that the MH-OW phenotype might be an independent protective factor for all-cause mortality.
An unusual, but understandable, finding was that participants with the MUH-NW phenotype were at the 
highest risk for all-cause mortality among 6 metabolic phenotypes (HR, 1.311, 95% CI, 1.162–1.479) in the 
present study. Consistent with our findings, several studies have shown that MUH-NW individuals were at 
increased risk for future cardiometabolic disease, including atrial fibrillation (26), hypertension (36), kidney 
disease (37), and death (27) compared with the MH-NW individuals. Similarly, in a pooled analysis of  8 stud-
ies, the MUH-NW group (RR, 3.14; 95% CI, 2.36–3.93) had the highest risk for all-cause mortality compared 
with individuals with the other 5 metabolic phenotypes (19). Consistent with these findings, we observed 
that there was a highest risk of  all-cause mortality in participants with the MUH-NW phenotype than in 
those with other phenotypes (HR, 1.311, 95% CI, 1.162–1.479). This counterintuitive and perhaps unexpect-
ed result might be explained by the fact that the MUH-NW phenotype represents the most severe subtype 
along the phenotypic spectrum of individuals genetically predisposed to cardiovascular events or death (19). 
Genetic analyses supported the notion that metabolically unhealthy phenotypes might be associated with 
body fat distribution patterns that favor visceral and ectopic fat accumulation over fat deposition in the periph-
ery (38, 39). Furthermore, MUH-NW is most strongly characterized by a low percentage of  gluteofemoral 
and leg fat mass (40). On the other hand, MUH-NW participants might have other undefined abnormalities 
(19, 41–43) or metabolic abnormalities, resulting in fat distribution changes (44, 45), which might contribute 
to this adverse phenotype. In addition, the finding is supported by the observation that MUH-NW groups had 
high percentage of  history of  diabetes compared with other group (Table 1). Consequently, substantial atten-
tion should be given to individuals with metabolically unhealthy status, despite normal weight.
MH-OW was found to be the healthiest metabolic phenotype, which is the most important finding of  
the present study. This large-scale prospective study, including approximately 100,000 participants who 
were followed-up for more than 10 years, might have resulted in the robust findings. Second, we first veri-
fied that MHO or MH-OW did not increase the risk for all-cause mortality in a Chinese population. At this 
point, the present study supported the concept that “all obesity is not created equally.” However, consider-
ing our previous finding that obesity was associated with a higher risk of  myocardial infarction, even with-
out measurable metabolic abnormalities (21), whether participants with the MHO or MH-OW phenotype 
should reduce their body weight needs further consideration.
Figure 3. Association of BMI-MetS phenotypes with all-cause mortality risk. Multivariate cox regression analysis was used to evaluate the association 
of all-cause mortality risk with BMI-MetS phenotypes, adjusting for potential confounding factors (n = 93,272). HR calculated by univariate cox regression 
(left), HR calculated by cox regression adjusting for age and sex (middle), and HR calculated by cox regression further adjusted for smoking, drinking, edu-
cation, BMI index, income, exercise, salt intake, and history of disease (hyperlipidemia, hypertension, diabetes, myocardial infarction, and stroke) (right) 
are shown. *Per 1,000 person-years. MH-NW, metabolically healthy normal weight; MUH-NW, metabolically unhealthy normal weight; MH-OW, metabol-
ically healthy overweight; MUH-OW, metabolically unhealthy overweight; MHO, metabolically healthy obesity; MUO, metabolically healthy obesity; MetS, 
metabolic syndrome.
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Figure 4. The sensitivity 
analyses of the association of 
all-cause mortality risk with 
BMI-MetS phenotypes. The 
association of all-cause mortality 
risk with BMI-MetS phenotypes 
excluding current smokers (A), 
excluding dead participants 
during the first 2 years (B), using 
WC instead of BMI and modifying 
the definition of MetS (≥2 among 
the 4 components excluding 
the WC criteria) (C), retaining 
participants aged 50–85 years 
(D). n = 61,002 (A); n = 93,272 
(B); n = 93,272 (C); n = 52,776 
(D). Multivariate cox regression 
analysis was used to evaluate the 
association of all-cause mortality 
risk with BMI-MetS phenotypes, 
adjusting for potential con-
founding factors. The asterisk 
indicates HR calculated by cox 
regression adjusting for age and 
sex, and the pound sign indicates 
HR calculated by cox regression 
further adjusting for smoking, 
drinking, education, BMI index, 
income, exercise, salt intake, 
dyslipidemia, and history of 
disease (hypertension, hyper-
lipidemia, diabetes, myocardial 
infarction, and stroke). MH-NW, 
metabolically healthy normal 
weight; MUH-NW, metaboli-
cally unhealthy normal weight; 
MH-OW, metabolically healthy 
overweight; MUH-OW, metaboli-
cally unhealthy overweight; MHO, 
metabolically healthy obesity; 
MUO, metabolically healthy 
obesity; MH-NO, metabolically 
healthy normal waist circum-
ference; MU-NO, metaboli-
cally unhealthy normal waist 
circumference; MetS, metabolic 
syndrome; WC, waist circumfer-
ence.
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Apart from its strengths, several limitations should be addressed. First, there is no universally accepted 
definition for metabolic health, such as, 0 or 1 cardiometabolic abnormalities, fewer than 2 signs of  metabolic 
components, or other criteria (46–48). Many previous studies have used the International Diabetes Federation 
criteria to define metabolic health as the presence of  less than 2 MetS components (21, 26, 49). Therefore, 
we also adopted the above criteria to define metabolic health. Second, metabolic health status might change 
over time, specifically among individuals with obesity (50, 51); therefore, the baseline status did not represent 
actual exposure in a longitudinal study. Third, although a range of  potential confounding factors was adjusted 
in the multivariate analysis, the bias resulting from unmeasured and residual confounding factors could not be 
completely avoided. Finally, the unbalanced sex ratio (Table 1) might restrict the generalization of  the present 
findings. However, the consistencies among sensitivity and stratified analyses might minimize the limitation.
In brief, the present study shows that overweight and obesity do not predict increased risk of  all-cause 
mortality in metabolic healthy Chinese individuals. Metabolic healthy overweight is the healthiest pheno-
type when only all-cause mortality was taken into account.
Methods
Study population. The Kailuan study is an ongoing prospective cohort study in Tangshan, China. This study 
was designed to investigate risk factors for chronic diseases (such as stroke, myocardial infarction, cancer, 
etc.). From June 2006 to October 2007, a total of  101,510 adults (81,110 men and 20,400 women) aged 
18–98 years were enrolled to participate in a routine medical examinations, which included physical exam-
ination, routine blood, urine, and biochemical tests every 2 years at 11 hospitals affiliated with the Kailuan 
Table 2. The association between BMI-MetS phenotypes and all-cause mortality in the whole group and stratified subgroups
MH-NW  
(reference group) MH-OW MHO MUH-NW MUH-OW MUO
P for 
Heterogeneity
Overall 1.000 0.926  (0.861–0.997)
1.009  
(0.886–1.148)
1.311  
(1.162–1.479)
1.135  
(1.023–1.260)
1.252  
(1.075–1.458) —
Sex
 Male 1.000 0.938  (0.869–1.012)
1.026  
(0.896–1.175)
1.235  
(1.072–1.012)
1.102  
(0.982–1.236)
1.198  
(1.015–1.413)
0.007
 Female 1.000 0.732  (0.544–0.986)
0.803 
(0.485–1.329)
1.535  
(1.183–1.991)
1.211  
(0.913–1.607)
1.354  
(0.866–2.117)
Age 
 <65 years 1.000 0.895  (0.807–0.993)
0.882  
(0.734–1.060)
1.538  
(1.298–1.823) 1.121 (0.970–1.296)
1.155  
(0.935–1.426)
 < 0.001
 ≥65 years 1.000 0.951  (0.857–1.055)
1.127  
(0.937–1.355)
1.133  
(0.950–1.345)
1.108  
(0.953–1.288)
1.217  
(0.972–1.524)
Smoking status
 No/former 1.000 0.895  (0.819–0.978)
0.969  
(0.828–1.133) 
1.310  
(1.136–1.510)
1.108  
(0.979–1.254)
1.204  
(1.004–1.444) 
0.957
 Current 1.000 0.990 (0.871–1.127) 
1.097  
(0.870–1.384) 
1.292  
(1.029–1.622) 
1.147  
(0.947–1.389) 
1.324  
(1.000–1.754) 
Drinking status
 No/former 1.000 0.928  (0.850–1.012) 
0.966  
(0.828–1.128) 
1.322  
(1.147–1.522)
1.137  
(1.007–1.285)
1.217  
(1.017–1.455) 
0.283
 Current 1.000 0.935  (0.817–1.069)
1.132  
(0.891–1.438) 
1.297  
(1.029–1.635) 
1.098  
(0.899–1.069) 
1.320  
(0.986–1.767) 
Physical activity 
 <3 times/
week 1.000 
0.910  
(0.838–0.988) 
0.971  
(0.839–1.124)
1.335  
(1.165–1.531) 
1.099  
(0.977–1.236)
1.279  
(1.077–1.518)
0.137
 ≥3 times/
week 1.000 
0.994  
(0.849–1.164)
1.162  
(0.877–1.539)
1.260 
 (0.974–1.629)
1.261  
(1.007–1.579)
1.127  
(0.808–1.571)
Data represent HR (95% CI). MH-NW was used as a reference group. Model was adjusted for age, sex, smoking, drinking, education, BMI index, income, 
exercise, salt intake, hyperlipidemia, and history of diseases (hypertension, diabetes, myocardial infarction, and stroke). MH-NW, metabolically healthy 
normal weight; MUH-NW, metabolically unhealthy normal weight; MH-OW, metabolically healthy overweight; MUH-OW, metabolically unhealthy 
overweight; MHO, metabolically healthy obesity; MUO, metabolically healthy obesity. P for heterogeneity was attained from the likelihood ratio test.
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community (52–54). In this analysis, we included participants from the Kailuan study, excluding partici-
pants with missing data for biochemical parameters, sociodemographic characteristics, history of  disease 
or current use of  medication (hypertension, diabetes, stroke, and myocardial infarction) and if  their BMI 
was less than 18.5 kg/m2 at baseline.
Exposure factors. BMI was calculated as weight in kilograms divided by height in meters squared, and 
participants were categorized into normal (18.50 kg/m2 ≤ BMI < 24.00 kg/m2), overweight (24.00 kg/
m2 ≤ BMI < 28.00 kg/m2), or obese (BMI ≥ 28.00 kg/m2) groups according to Chinese-specific criteria 
(55). Based on the modified International Diabetes Federation criteria for the Asian population, MetS was 
defined as the presence of  3 or more abnormal components (WC ≥80 cm in women and ≥90 cm in men; 
TG ≥1.70 mmol/L or current use of  lipid-lowering agents; diastolic blood pressure ≥85 mmHg, systolic 
blood pressure ≥130 mmHg, or self-reported history of  hypertension or current use of  blood pressure med-
ication; FGB level ≥5.60 mmol/L, current use of  glucose-lowering agents or self-reported history of  dia-
betes; and HDL-C <1.03 mmol/L for men and <1.30 mmol/L for women or current use of  lipid-lowering 
agents) (56). Metabolically healthy (MH) was defined as the presence of  2 or less abnormal components, 
while metabolically unhealthy (MUH) was defined as the presence of  3 or more abnormal components. 
Combined with BMI category (normal weight, overweight, and obesity), metabolic healthy participants 
were divided into 3 phenotypes, MH-NW, MH-OW, and MHO, and metabolic unhealthy participants were 
divided as well, MUH-NW, MUH-OW, and MUO (21, 46).
Covariables. Face-to-face questionnaire interviews and clinical examinations were conducted by well-
trained medical staff  following a standard protocol to collect information on sociodemographic charac-
teristics, lifestyle factors, and medical history (57). Smoking and drinking status were divided into 3 cate-
gories: never, former, and current (21, 52). Physical activity was evaluated with regard to the frequency of  
physical activity, including inactive; moderately active, 1–2 times/week; and vigorously active, ≥3 times/
week and ≥30 minutes (53). In addition, levels of  FBG, TG, and HDL-C were measured using an autoan-
alyzer (Hitachi 747) at the central laboratory of  Kailuan General Hospital (58).
Follow-up and outcome. All participants were followed by face-to-face interviews at every 2-year routine 
medical examination until December 31, 2017, or until death. The follow-ups were performed by hospital 
physicians, research physicians, and research nurses, who were blinded to the baseline data. For the partic-
ipants without face-to-face follow-up, the follow-up information was collected by referring to death certifi-
cates from provincial vital statistics offices, discharge summaries from the 11 hospitals, or medical records 
from medical insurance (59).
We used all-cause death as the primary outcome. Considering unnatural death, we excluded the acci-
dental deaths, which were transport-related accidents, violence, falling, natural hazard, medical malprac-
tice, and food poisoning. Deaths were assessed using family report, death certificates from provincial vital 
statistics offices, and medical records from medical insurance or hospitals (52).
Statistics. The baseline characteristics of  participants are presented as mean ± standard deviation or 
median with interquartile range for continuous variables and percentage for categorical variables. χ2 tests 
were used for the comparisons of  categorical variables. The analysis of  variance or Kruskal-Wallis tests 
were used for continuous variables. Person-years were calculated from the date of  baseline examination to 
the date of  death or the end of  follow-up (December 31, 2017), whichever came first. The cumulative mor-
tality among 6 phenotype groups was estimated using the Kaplan-Meier method and compared by log-rank 
tests. The Sidak method was used to adjust P values in the multiple comparisons (21).
Cox proportional hazards regression was used to estimate HRs and 95% CIs for the association between 
the 6 BMI-MetS groups and all-cause mortality risk. The proportional hazards assumption was tested by 
the Schoenfeld residuals (21), and no violation was found. We fitted 3 Cox proportional hazard models. 
Model 1 was a crude model without adjusted covariates. Model 2 was adjusted for age and sex. Model 3 
was further adjusted for smoking status, drinking status, educational level, family per-member monthly 
income, physical activity, salt intake, dyslipidemia, and history of  disease.
To test the robustness of  the main results, we conducted 4 sensitivity analyses in model 1 and model 
3. We excluded participants who were current smokers at baseline or died during the first 2 years of  fol-
low-up. In addition, we defined obesity using WC instead of  BMI and defined MetS as having 2 or more of  
4 metabolic components (excluding WC criteria). Participants were classified into the following 4 groups: 
no obesity (WC <80 cm in women and <90 cm in men) without MetS (MH-NO) or with MetS (MU-NO), 
MHO (obesity defined as WC ≥80 cm in women and ≥90 cm in men), and MUO. We retained participants 
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who were 50–85 years for avoiding differences in mortality for this reason of  age. Likelihood ratio test was 
conducted to examine statistical interactions among BMI-MetS groups, sex, age (<65 years, ≥65 years), 
smoking status, drinking status, and physical activity in association with all-cause mortality by comparing 
–2 log likelihood χ2 between nested models, with or without the multiplication interaction terms.
All statistical analyses were conducted using SAS, version 9.4(SAS Institute Inc). Two-sided P < 0.05 
was considered statistically significant.
Study approval. This study was approved by the ethics committees of  Kailuan General Hospital and 
Beijing Tiantan Hospital, Capital Medical University. Written informed consent form was obtained 
from all participants.
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